Notice2022-28357
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 29, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Affini-T Therapeutics, Inc. ("Affini-T"), headquartered in Watertown, MA.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 249 (Thursday, December 29, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 249 (Thursday, December 29, 2022)]
[Notices]
[Pages 80190-80191]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-28357]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Development and
Commercialization of Engineered Cell Therapies for the Treatment of
Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this Notice to Affini-T
Therapeutics, Inc. (``Affini-T''), headquartered in Watertown, MA.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before January 13, 2023 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer
Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484;
Email: <a href="/cdn-cgi/l/email-protection#365758524f185443445d5376585f5e18515940"><span class="__cf_email__" data-cfemail="9ffef1fbe6b1fdeaedf4fadff1f6f7b1f8f0e9">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 63/185,805
filed May 7, 2021, entitled ``T Cell Receptors Recognizing C135Y, R175H
or M237I Mutation in P53'' [HHS Reference No. E-101-2021-0-US-01]; and
2. PCT Application No. PCT/US2022/028066 filed May 6, 2022,
entitled ``T Cell Receptors Recognizing C135Y, R175H or M237I Mutation
in P53'' [HHS Reference No. E-101-2021-0-PCT-02].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Development, manufacture and commercialization of T or Natural
Killer cell therapy products genetically engineered to express the P53
R175H-reactive T cell receptor claimed in the Licensed Patent Rights
for the treatment of cancer in humans.''
E-101-2021 patent family is primarily directed to isolated TCRs
reactive to certain mutated forms of tumor protein 53 (TP53 or P53),
within the context of several human leukocyte antigens. P53 is the
archetypal tumor suppressor gene and the most frequently mutated gene
in cancer. Contemporary estimates suggest that >50% of all tumors carry
mutations in P53. Because of its prevalence in cancer and its
restricted expression to precancerous and cancerous cells, this antigen
may be targeted on mutant P53-expressing tumors with minimal normal
tissue toxicity.
[[Page 80191]]
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published Notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially and may be made
publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: December 22, 2022.
Richard U. Rodriguez,
Associate Director,Technology Transfer Center,National Cancer
Institute.
[FR Doc. 2022-28357 Filed 12-28-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 29, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.